文献速递白血病造血干细胞移植与细胞治疗

rhG-CSF联合小剂量地西他滨预防高危MRD阴性AML移植后复发

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2020-10-27

结果显示G-Dec组2年累积复发率显著低于非G-Dec组(15.0% vs 38.3%,P<.01),且不增加无复发的慢性GVHD发生率。

要点

  • 移植后60-100天MRD阴性的HR-AML患者,rhG-CSF联合小剂量Dec可降低2年累积复发率。
  • 联合方案未显著增加2年无复发cGVHD累积发生率(23.0% vs 21.7%,P=.82)。
  • 维持治疗后观察到NK细胞、CD8+ T细胞和调节性T细胞数量增加。

核心结论

  • allo-HSCT后使用rhG-CSF联合小剂量Dec维持治疗可降低HR-AML患者复发率,并伴随淋巴细胞亚型数量变化。

主要发现

  • G-Dec组2年累积复发率为15.0%(95%CI 8.0%-22.1%),非G-Dec组为38.3%(95%CI 28.8%-47.9%),P<.01,HR=0.32(95%CI 0.18-0.57;P<.01)。
  • 两组2年无复发cGVHD累积发生率分别为23.0%(95%CI 14.7%-31.3%)和21.7%(95%CI 13.6%-29.7%),P=.82,HR=1.07(95%CI 0.60-1.92;P=.81)。
  • rhG-CSF联合小剂量Dec维持治疗后,观察到自然杀伤细胞、CD8+ T细胞和调节性T细胞数量增加。

临床怎么用

  • 对于allo-HSCT后60-100天且MRD阴性的HR-AML患者,可考虑rhG-CSF联合小剂量Dec维持治疗以降低复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML). The aim of this study was to explore the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) combined with minimal-dose decitabine (Dec) on the prevention of HR-AML relapse after allo-HSCT. PATIENTS AND METHODS: We conducted a phase II, open-label, multicenter, randomized controlled trial. Two hundred four patients with HR-AML who had received allo-HSCT 60-100 days before randomization and who were minimal residual disease negative were randomly assigned 1:1 to either rhG-CSF combined with minimal-dose Dec (G-Dec group: 100 µg/m2 of rhG-CSF on days 0-5 and 5 mg/m2 of Dec on days 1-5) or no intervention (non-G-Dec group). The primary outcome was relapse after transplantation, and the secondary outcomes were chronic graft-versus-host disease (cGVHD), safety of the treatment, and survival. RESULTS: The estimated 2-year cumulative incidence of relapse in the G-Dec group was 15.0% (95% CI, 8.0% to 22.1%), compared with 38.3% (95% CI, 28.8% to 47.9%) in the non-G-Dec group (P < .01), with a hazard ratio (HR) of 0.32 (95% CI, 0.18 to 0.57; P < .01). There was no statistically significant difference between the G-Dec and non-G-Dec groups in the 2-year cumulative incidence of cGVHD without relapse (23.0% [95% CI, 14.7% to 31.3%] and 21.7% [95% CI, 13.6% to 29.7%], respectively; P = .82), with an HR of 1.07 (95% CI, 0.60 to 1.92; P = .81). After rhG-CSF combined with minimal-dose Dec maintenance, increasing numbers of natural killer, CD8+ T, and regulatory T cells were observed. CONCLUSION: Our findings suggest that rhG-CSF combined with minimal-dose Dec maintenance after allo-HSCT can reduce the incidence of relapse, accompanied by changes in the number of lymphocyte subtypes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol. 2020. PMID: 33108244. doi:10.1200/JCO.19.03277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。